Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 4/20 | 0.38 |
| ▸ | MAPKAPK2 | P49137 | 4/20 | 0.37 |
| ▸ | STK17B | O94768 | 1/20 | 0.36 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | NNMT | P40261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20839014 | 0.85 | LCK (0.43) | ATRLCKMAPKAPK2STK17BSTK17A | |
| SCHEMBL32681564 | 0.84 | SYK (0.39) | ATRMAPKAPK2STK17BSTK17ANPSR1 | |
| SCHEMBL20843701 | 0.76 | ATR (0.37) | ATRLCKMAPKAPK2GSK3BDYRK1A | |
| SCHEMBL3956108 | 0.75 | ATR (0.43) | ATRLCKNPSR1 | |
| SCHEMBL32681571 | 0.75 | SIRT6 (0.42) | ATRMAPKAPK2MEN1PABPC1KMT2A | |
| SCHEMBL2885204 | 0.74 | MAPKAPK2 (0.41) | ATRLCKMAPKAPK2STK17BSTK17A | |
| SCHEMBL28458230 | 0.74 | ATR (0.40) | ATRSTK17BSTK17AMEN1KMT2A | |
| SCHEMBL7462692 | 0.72 | ATR (0.42) | ATRLCKMAPKAPK2STK17BSTK17A | |
| SCHEMBL31418600 | 0.72 | LCK (0.41) | LCK | |
| SCHEMBL7416577 | 0.72 | LCK (0.45) | ATRLCKMAPKAPK2GSK3BDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149718-A1 | Amido Compounds | BROTHERTON-PLEISS CHRISTINE E (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149718-A1 | Amido Compounds | P2RX7, P2RX3, P2RX2 | ATR 3534/4885LCK 2116/4885MAPKAPK2 3004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.